Top Markets
Coin of the day
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Rangering i aksjer #38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Aksjekurs
$0.1645
Markedsverdi
$681.26K
Endring (1 dag)
-3.69%
Endring (1 år)
-95.30%
Land
US
Handel Valion Bio, Inc. (VBIO)

Kategori

P/B-forhold for Valion Bio, Inc. (VBIO)
P/B-forhold per 2026 TTM: 0
Ifølge Valion Bio, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Valion Bio, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE